Link: http://www.otcmarkets.com/stock/PMCB/company-info Ticker: $PMCB OTC Market Place: OTCQB CIK code: 0001157075 Company name: PharmaCyte Biotech, Inc. Company website: http://http://www.PharmaCyte.com Incorporated In: NV, USA
Business Description: PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as \"Cell-in-a-Box\" This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer and its symptoms, and diabetes are being developed. PharmaCyte Biotech's treatment for solid tumor cancers involves encapsulating modified live cells capable of converting the prodrug ifosfamide into its active or \"cancer-killing\" form. These encapsulated live cells are placed as close to the tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. Ifosfamide is then given intravenously at one third the normal dose to eliminate adverse side effects. When the ifosfamide comes in contact with the encapsulated live cells through the circulatory system, the activation of the drug takes place at or near the tumor. This \"targeted chemotherapy\" has proven remarkably effective and safe to use in past clinical trials. PharmaCyte Biotech is also developing treatments for cancer based upon chemical constituents of the Cannabis plant. It is examining ways to exploit the benefits of Cell-in-a-Box technology in optimizing the anticancer effectiveness of Cannabis, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. In addition to developing treatments for pancreatic and other cancers, PharmaCyte Biotech is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte Biotech plans to encapsulate a human cell line which has been genetically engineered to produce, store and secrete insulin on demand at levels in proportion to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box technology.Less >>
$PMCB share structure
## source: otcmarkets.com
Market Value: $48,052,917 a/o Feb 19, 2016 Shares Outstanding: 750,826,823 a/o Dec 10, 2015 Float: 529,206,849 a/o Aug 26, 2014 Authorized Shares: 1,490,000,000 a/o Aug 26, 2014 Par Value: 0.0001
i see dis/ USAR Announces Engagement Agreement with NAUP Capital, LP for Strategy & Business Development Services Posted on Tuesday February 02, 2016 [PR Newswire] - DALLAS, Feb. 2, 2016 /PRNewswire/ -- The Chron Organization, Inc. formerly known as USA Restaurant Funding, Inc. (OTCPK: USAR) announced today that it has retained the services of the prestigious Dallas-based, ...
news ????? GEQU, GLOBAL MARKETS-Oil turns higher, pushes world stock markets up Posted on Thursday February 25, 2016 [Reuters - UK Focus] - Global equity (OTC BB: GEQU - news) markets got a boost from an upturn in crude oil on Thursday as the market focused on an upcoming meeting of major oil producers that investors hope could stabilize volatile petroleum markets. Crude oil futures rose more than 2 percent after Venezuela reaffirmed an oil producers meeting in mid-March that would include Saudi Arabia, Russia and Qatar.
Market Data 
Markets 
AI
